Dr. Tripathy on the Management of HR+ Early-Stage Breast Cancer

Copy of Dr. Tripathy on the Management of HR+ Early-Stage Breast CancerПодробнее

Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...Подробнее

Depu Tripathy on Lower Risk for Recurrence of Early Stage Breast CancerПодробнее

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast CancerПодробнее

Dr. Tripathy Discusses Breast Cancer BiomarkersПодробнее

Rethinking Breast Cancer: Optimal Trial Design and Exploring Novel ModalitiesПодробнее

Dr. Tripathy on Targeting HER2 in Breast CancerПодробнее

Dr. Tripathy on Genomically Guided Therapy in Breast CancerПодробнее

Dr. Tripathy Discusses Breast Cancer Gene ProfilingПодробнее

Dr.Tripathy on Targeting HER2 in Breast CancerПодробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

Personalized Medicine in the Genomic Age of Breast Cancer by Dr. TripathyПодробнее

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast CancerПодробнее

Dr. Tripathy on the Treatment of Breast Cancer With Anthracyclines and TrastuzumabПодробнее

Dr. Tripathy Discusses Breast Cancer PreventionПодробнее

Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast CancerПодробнее

Role of endocrine therapy in early-stage HR-positive breast cancerПодробнее

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast CancerПодробнее

Debu Tripathy on Hormonal Therapy for Breast CancerПодробнее